| Literature DB >> 6406454 |
N Harto-Truax, W C Stern, L L Miller, T L Sato, A E Cato.
Abstract
Patients' weights were assessed during placebo-controlled, amitriptyline-controlled, and uncontrolled bupropion trials. Low-moderate (50-450 mg/day) to moderate-high (300-750 mg/day) doses of bupropion were consistently associated with a lack of weight gain (average weight loss of 1-2 pounds); placebo was associated with an average weight gain of 1 lb and 75-225 mg/day of amitriptyline was associated with an increase of 3-9 lb. Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo.Entities:
Mesh:
Substances:
Year: 1983 PMID: 6406454
Source DB: PubMed Journal: J Clin Psychiatry ISSN: 0160-6689 Impact factor: 4.384